What’s the best light therapy schedule for young people with depression?
The best supported answer is a cumulative dose rather than a fixed daily routine: when light therapy delivered a high circadian stimulus (0.6 < CSt,f < 0.7), 1,000 to 1,500 minutes of accumulated exposure produced a significantly greater effect than under 1,000 minutes or over 1,500 minutes. That threshold comes from a systematic review and meta-analysis of 31 articles covering 1,031 adolescents and young adults, not from a single trial, and the authors themselves call the superiority of higher circadian stimulus over dimmer light controls unproven.
The review quantified each study's light exposure with circadian light (CLa) and circadian stimulus (CSt,f) models, so the dose is expressed as circadian stimulation and accumulated minutes rather than lux at the eye.
What the pooled data support:
- Cumulative duration: more influential on pre-to-post improvement than circadian stimulus, co-medication, severity, or study design
- Saturation with co-medication: 32 to 42 days, 900 to 1,000 minutes
- Saturation without medication: 58 to 59 days, 1,100 to 1,500 minutes
- Threshold at high circadian stimulus: 1,000 to 1,500 minutes of accumulated exposure
- Versus dim red light: bright light therapy was significantly better, SMD -0.65
- Versus dimmer white light: bright light therapy was significantly better, SMD -0.37
A systematic review and meta-analysis in Frontiers in Public Health pooled 31 articles and 1,031 subjects, reporting symptom reduction across circadian stimulus conditions from 0.1 to 0.7.
Dr. Kumar’s Take
I would not read this as a finished prescription. It is a modeling exercise laid over 31 heterogeneous studies, and the authors are candid that the samples are limited, that a small sample effect shaped the results, and that placebo cannot be ignored. The part I find genuinely useful is the reframing of dose. Instead of arguing about lux, the authors converted every study’s light into a circadian stimulus and then asked how many total minutes it takes to get the benefit. Cumulative duration mattered more than the intensity of the circadian stimulus itself, which fits what I see clinically: consistency over weeks beats a heroic single session. The co-medication signal is the other thing I will carry into practice. Co-medicated patients reached saturation at 32 to 42 days, while those not on medication needed 58 to 59 days, so I would set expectations differently depending on whether light is an add-on or a standalone. What this review does not settle is whether the circadian mechanism is doing the work. Bright light beat dim red and dimmer white controls, but green-blue bright light showed no significant advantage over red or amber controls, and participants can see which arm they are in. I treat this as a dosing map with an unresolved mechanism, not as proof.
Study Snapshot
This is a systematic review and meta-analysis, not a clinical trial. The authors searched Web of Science, Cochrane Library, MEDLINE (Ovid), CINAHL, APA PsycINFO, Embase, and Scholars for articles published up to 2023, then pooled 31 articles covering 1,031 subjects, all adolescents and young adults with depression-related conditions. Light exposure in each study was converted into circadian light (CLa) and circadian stimulus (CSt,f) values so that doses could be compared on a common circadian scale, with circadian stimulus conditions spanning 0.1 to 0.7. Analyses were run in Stata 17.0, Comprehensive Meta-Analysis 3.0, and Python 3.9, using standardized mean differences for efficacy comparisons and dose-response fitting for cumulative exposure.
Results in Real Numbers
- Overall effect: pooled SMD -1.59 (95% CI -1.86 to -1.32; z = -11.654; p = 0.000; I² = 92.8%) across 31 articles and 1,031 subjects
- Heterogeneity sources: temporal pattern (p = 0.044) and co-medication (p = 0.000)
- Bright light vs dim red light: SMD -0.65 (95% CI -0.96 to -0.34; z = -4.101; p = 0.000; I² = 84.9%)
- Bright light vs circadian-active dimmer white light: SMD -0.37 (95% CI -0.68 to -0.06; z = -2.318; p = 0.02; I² = 33.8%)
- Green-blue bright light vs red or amber controls: SMD -0.21 (95% CI -0.45 to 0.04; p = 0.099; I² = 0%), not significant
- Saturation, co-medicated: 32 to 42 days, 900 to 1,000 cumulative minutes
- Saturation, non-medicated: 58 to 59 days, 1,100 to 1,500 cumulative minutes
- Clinical response: circadian-active bright light therapy showed a greater likelihood of clinical response than dim light controls, with the advantage increasing alongside co-medication
Who Benefits Most
Patients already on medication reached therapeutic saturation at 32 to 42 days of cumulative exposure, against 58 to 59 days for those not medicated, and the response advantage of bright light over dim light controls increased with co-medication. Co-medication was also one of the two main sources of heterogeneity across the pooled studies (p = 0.000), which is why the authors treat medication status as a defining variable rather than a footnote.
Patients who accumulate enough total exposure. Cumulative duration was the strongest predictor of pre-to-post improvement, ahead of circadian stimulus level, disease severity, and study design. At a high circadian stimulus of 0.6 to 0.7, the 1,000 to 1,500 minute band outperformed both shorter and longer accumulations.
Patients receiving genuinely bright light rather than dim controls. Circadian-active bright light therapy beat circadian-inactive dim red light and circadian-active dimmer white light. It did not beat red or amber controls when the bright light was green-blue, so the benefit cannot be attributed to circadian stimulus alone on this evidence.
Safety, Limits, and Caveats
The core superiority question is unresolved. The authors state directly that the superiority of light therapy with higher circadian stimulus over dimmer light controls remains unproven. The green-blue comparison against red and amber controls was null (SMD -0.21, p = 0.099).
High heterogeneity. The pooled analysis carried I² = 92.8%, with temporal pattern and co-medication identified as the main sources. Efficacy across conditions was also assumed to be influenced by visualization, disease severity, and time pattern.
Placebo cannot be ruled out. The review lists the placebo effect as a limitation that could not be ignored. Bright light and dim controls differ in ways participants can see, which makes blinding difficult.
Limited samples. The authors note that their results rest on limited samples and were influenced by a small sample effect, which constrains how far the dose-response fitting should be pushed.
More is not better past the threshold. At high circadian stimulus, accumulations beyond 1,500 minutes showed a smaller effect than the 1,000 to 1,500 minute band.
Practical Takeaways
- Think in total minutes, not just daily sessions. Cumulative duration outweighed circadian stimulus, severity, and study design as a predictor of improvement.
- Aim for 1,000 to 1,500 cumulative minutes when the light delivers a high circadian stimulus. Less and more both underperformed that band.
- Set the timeline by medication status. Saturation came at 32 to 42 days with co-medication and 58 to 59 days without.
- Use light that is actually bright, not a dim substitute. Bright light therapy outperformed both dim red light and dimmer white light controls.
- Do not promise a circadian mechanism. Green-blue bright light showed no significant advantage over red or amber controls.
- Treat these targets as provisional. The pooled estimates come from limited samples with high heterogeneity and an unresolved placebo contribution.
What This Means for Youth Mental Health
This review gives clinicians something they did not have before: a way to compare light doses across studies on a single circadian scale, and a cumulative exposure target attached to it. The 1,000 to 1,500 minute band at high circadian stimulus, and the split between 32 to 42 days with medication and 58 to 59 days without, are concrete enough to plan around and to explain to a patient who wants to know when to expect a change.
What it does not give is proof that circadian stimulation is the active ingredient. Bright light beat dimmer controls, but the comparison designed to isolate the circadian pathway came out null, and the authors flag limited samples and placebo as live problems. I would use these numbers to structure a trial of light therapy in a young patient, particularly as an add-on to an antidepressant, and I would keep reassessing rather than assume the dose curve is settled.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Light Therapy for Dementia: Sleep, Depression, and Cognition
FAQs
What’s the best light therapy schedule for young people with depression?
The review supports a cumulative dose rather than a fixed daily routine. When the light delivered a high circadian stimulus (0.6 < CSt,f < 0.7), 1,000 to 1,500 minutes of accumulated exposure produced a significantly greater effect than under 1,000 or over 1,500 minutes. Cumulative duration mattered more than the circadian stimulus level itself.
Does light therapy work better with medication?
The pooled data point that way. Circadian-active bright light therapy showed a greater likelihood of clinical response than dim light controls, and that advantage increased with co-medication. Co-medicated patients also reached saturation at 32 to 42 days, compared with 58 to 59 days for non-medicated patients. Co-medication was one of the two main sources of heterogeneity across studies (p = 0.000).
How long does light therapy take to work in young people?
Dose-response fitting put saturation at 32 to 42 days, or 900 to 1,000 cumulative minutes, among co-medicated patients, and at 58 to 59 days, or 1,100 to 1,500 cumulative minutes, among non-medicated adolescents and young adults.
Bottom Line
This systematic review and meta-analysis of 31 articles and 1,031 adolescents and young adults found significant symptom reduction with light therapy across circadian stimulus conditions from 0.1 to 0.7 (pooled SMD -1.59, 95% CI -1.86 to -1.32). Bright light therapy beat dim red light (SMD -0.65) and dimmer white light (SMD -0.37), but not red or amber controls when the bright light was green-blue, so the authors conclude that the superiority of higher circadian stimulus over dimmer controls remains unproven. The most usable output is the dosing map: saturation at 32 to 42 days with co-medication and 58 to 59 days without, and a 1,000 to 1,500 minute cumulative threshold at high circadian stimulus. Heterogeneity was high, samples were limited, and placebo could not be ruled out.
